{
    "nctId": "NCT03647514",
    "briefTitle": "Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer",
    "officialTitle": "A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Operable Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "ORR(CR+PR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Provision of informed consent\n2. Women and men at least 18 years of age or older.\n3. Pathological confirmation of breast cancer\n4. Tumor stage(TNM):T2-4N0-3M0\n5. No evidence of distant metastasis\n6. Adequate bone marrow, hepatic, and renal function\n7. Measurable disease as per RECIST criteria\n8. Karnofsky\u226570\n9. Laboratory criteria:\n\nPLT\u2265100\\*109/L WBC\u22654000/mm3 HGB\u226510g/dl ALT and AST\\<2\\*ULN\n\nExclusion Criteria:\n\n1. Presence of metastatic disease.\n2. Inflammatory breast cancer.\n3. Bilateral breast cancer.\n4. previous chemotherapy or hormonal therapy for current breast neoplasm.\n5. other malignant tumors (concurrent or previous).\n6. Pregnant woman.\n7. Hypersensitive to any drug in Abraxane or Xeloda regimen or any ingredient of Abraxane or Xeloda.\n8. Any severe systemic disease contraindicating chemotherapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}